Considerations for nonsteroidal anti-inflammatory drug therapy: Safety

Scandinavian Journal of Rheumatology

Volumn 25, Issue SUPPL. 105, 1996, Pages 13-26

  Blower, A L ^a  

^a Royal Infirmary   (United Kingdom)

Author keywords

gastrointestinal toxicity; NSAIDs; rheumatoid arthritis; ulcer prevention

Indexed keywords

MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE;

CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; PAIN; PEPTIC ULCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS; ARTHRITIS; CHEMICALLY INDUCED DISORDER; DIGESTIVE SYSTEM; DRUG EFFECT; GASTROINTESTINAL DISEASE; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; DIGESTIVE SYSTEM; GASTROINTESTINAL DISEASES; HUMANS;

EID: 0029794674     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009749609097232     Document Type: Article

References (51)

1. Committee on the Safety of Medicines. CSM update: nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-I. BMJ 1986; 292:614.
2. Committee on the Safety of Medicines. CSM update: nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions2. BMJ 1986; 292: 1190-1.
3. FDA's NSAID class labeling estimate of 66% GI adverse reactions annually is not valid, PMA maintains. PMA proposes industry-consensus NSAID label warning. FDC Reports November 30, 1987:8-9.
4. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991: 17 16-25.
5. Brune K, Graft P. Non-steroid anti-inflammatory drugs; influence of extracellular pH on biodistribution and pharmacologic effects. Biochem Pharmacol 1978; 27525-30.
6. Cummings NA, Nordby GL. Measurement of synovial fluid pH in normal and arthritic knees. Arthritis Rheum 1966; 9147-56.
7. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 861449-58.
8. Shorrock CJ, Rees WD. Overview of gastroduodenal mucosal protection. Am J Med 1988; 84(Suppl. 2A):25-34.
9. Davenport HW, Warner HA, Code CF. Functional significance of gastric mucosal barrier to sodium. Gastroenterology 1964; 47: 142-52.
10. Hills RA, Butler BD, Lichtenberger LM. Gastric mucosal barrier: hydrophilic lining to the lumen of the stomach. Am J Physiol 1983; 244:G561-8. (Pubitemid 13101277)
11. Guth PH. Local metabolism and circulation in mucosal defense. In: Allen A, et al. (eds). Mechanisms of Mucosal Protection in the Upper Gastrointestinal Tract. New York, NY: Raven Press; 1984:253-8.
12. Wallace JL. Increased resistance of the rat gastric mucosa to hemorrhagic damage after exposure to an irritant: role of the "mucoid cap" and prostaglandin synthesis. Gastroenterology 1988; 94:22-32. (Pubitemid 18029755)
13. Main M III, Whittle BJR. The effects of E and A prostaglandins on gastric mucosal blood flow and acid secretion in the rat. Br J Pharmacol 1973; 49:428.
14. 2, and carbenoxolone. Gastroenterology 1981; 80:770.
15. McQueen S, Hutton D, Allen A, et al. Gastric and duodenal surface mucus gel thickness in rat: effects of prostaglandins and damaging agents. Am J Physiol 1983; 245:388.
16. Bolton JP, Cohen MM. Stimulation of non-parietal cell secretion in canine Heidenhain pouches by 16,16-dimethyl prostaglandin E2. Digestion 1978; 17:291.
17. Kauffman GL, Reeve JJ, Grossman MI. Gastric bicarbonate secretion: effect of topical and intravenous 16.1 6-dimethyl prostaglandin E2. Am J Physiol 1980; 239:44.
18. Gerber JG, Neis AS. Canine gastric mucosal vasodilation with prostaglandins and histamine analogs. Dig Dis Sci 1982; 27:870.
19. l) on lysosomal enzyme release in serotonin-induced gastric ulceration. Ann Surg 1973; 177:643.
20. Gryglewski RJ, Szczeklik A, Wandzilak M. The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl- leucyl phenylalanine. Biochem Pharmacol 1987; 36:4209.
21. Kainoh M, Imai R, Umetsu H, et al. Prostacyclin and beraprost sodium as suppressers of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39:477.
22. 2 or sodium thiosulfate. Gastroenterology 1986; 91:1415.
23. Geis GS, Stead H, Wallenmark C-B, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with RA or OA, and interim report on prevention by misoprosto1 of diclofenac-associated lesions. J Rheumatol 1991 ; 18(Suppl. 28):11-4.
24. Nobunaga M. Epidemiology study of upper gastrointestinal lesions induced by nonsteroidal anti-inflammatory drugs. Ryumachi 1991; 31:96-111.
25. Roth S, Agrawal N, Mahowald M, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149:775-9. (Pubitemid 19132996)
26. Farah D, Sturrock RD, Russell RI. Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis 1988; 47:472-80.
27. Collins AJ, Davies J. Dixon ASJ. Contrasting presentation and findings between patients with rheumatic complaints taking nonsteroidal anti-inflammatory drugs with a general population referred for endoscopy. Br J Rheumatol 1986; 25150-3.
28. Sontag S, Schnell T, Mak E, et al. NSAlDs with or without prednisone: bad news for the gut mucosa. Gastroenterology 1989; 96:A483.
29. Collins AJ, Du Toit JA. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol 1987; 26:295-8. (Pubitemid 17103853)
30. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic drug use. Am J Gastroenterol 1987; 82:1153-5.
31. Morris AD, Holt SD, Silvoso GR, et al. Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis: an endoscopic assessment. Scand 3 Gastroenterol 1981; 67(Suppl.): 131-5. (Pubitemid 11123074)
32. Semble EL, Turner RA, Wu WC. Clinical and genetic characteristics of upper gastrointestinal disease in rheumatoid arthritis. J Rheumatol 1987; 14:692-9. (Pubitemid 17137481)
33. Morgan R. Non-aspirin nonsteroidal anti-inflammatory drugs and active gastroduodenal ulceration in the elderly. Br J Rheumatol 1987; 16:158-9.
34. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; L462-4.
35. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28527-32.
36. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109:359-63.
37. Silvoso G, lvey KJ, Butt J, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91517-20.
38. Caruso I. Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980; 280:75-8. (Pubitemid 10199280)
39. Skander MP, Ryan Fp. Non-steroidal anti-inflammatory drugs and pain-free peptic ulceration in the elderly. BMJ 1988; 297S33-4.
40. Blower AL, Brooks A, Hill A. et al. Emergency admissions and deaths from upper gastrointestinal (UGI) crises in relation to NSAID use (abstract). Gut 1994; 35(Suppl. 2):S45.
41. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986; 76:3924.
42. Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an "acceptable" risk in the treatment of rheumatic disease? Br J Rheumatol 1990; 29:2 15-8.
43. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial with ranitidine. Br Med J 1988; 297;1017-21.
44. Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989; 34:424-8. (Pubitemid 19088785)
45. Gudjonsson H, Oddsson E, Thjodleifsson B. Protective effect of sucralfate against naproxen-induced damage to the human gastroduodenal mucosa (abstract). Scand J Gastroenterol 1990; 25(Suppl. 176):13.
46. Agrawal NM, Roth S. Graham DY, et al. Comparison of misoprostol and sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
47. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: a multicentre, double-blind, placebo-controlled trial. Lancet 1988; 11:1277-80.
48. Graham DY, White RH. Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119:25743.
49. Geis GS, Erhardt LJ, Stead H. Prevention of diclofenacinduced gastroduodenal mucosal lesions by misoprostol: a multinational, placebo-controlled, parallel group study (abstract). Hungarian Rheumatol 1991; 32:366.
50. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of NSAID-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123:344-50.
51. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebocontrolled trial. Ann Intern Med 1995; 123:241-9.